ROSES-S : Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2
© 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd..
Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies-SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 15(2021), 5 vom: 16. Sept., Seite 561-568 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
World Health Organization Seroepidemiology Technical Working Group [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Emerging |
|---|
| Anmerkungen: |
Date Completed 22.11.2021 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/irv.12870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327207981 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327207981 | ||
| 003 | DE-627 | ||
| 005 | 20231225200252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.12870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327207981 | ||
| 035 | |a (NLM)34173715 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a World Health Organization Seroepidemiology Technical Working Group |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ROSES-S |b Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. | ||
| 520 | |a Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies-SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a emerging | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a seroepidemiologic Studies | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 15(2021), 5 vom: 16. Sept., Seite 561-568 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:5 |g day:16 |g month:09 |g pages:561-568 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.12870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 5 |b 16 |c 09 |h 561-568 | ||